LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway-Reference-Cited by-同舟云学术

LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway

Published:2021-09-30 Issue:22 Volume:81 Page:5678-5691
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Xu Fengyu,Huang Mengqi,Chen Qingyong,Niu Yi,Hu Yuhang,Hu Ping,Chen Ding,He Chi,Huang Kang,Zeng Zhu,Tang Jiang,Wang Fan,Zhao Yong,Wang Chunyou,Zhao Gang

Funder

Clinical Research Physician Program of Tongji Medical CollegeHuazhong University of Science and TechnologyNational Natural Science Foundation of ChinaNational Natural Science Foundation of China

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological inhibition of SREBP1 suppresses pancreatic cancer growth via inducing GPX4-mediated ferroptosis;Cellular Signalling;2024-12

2. Regulatory function of glycolysis-related lncRNAs in tumor progression: Mechanism, facts, and perspectives;Biochemical Pharmacology;2024-11

3. Glycolysis-associated lncRNAs in cancer energy metabolism and immune microenvironment: a magic key;Frontiers in Immunology;2024-09-13

4. LPCAT2-mediated lipid droplet production supports pancreatic cancer chemoresistance and cell motility;International Immunopharmacology;2024-09

5. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein;Drug Resistance Updates;2024-09